drugset / Trial / NCT00002315

A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems

NCT00002315

Phase 3 Completed 400 enrolled Glaxo Wellcome
Double-blindTreatment

Summary

To determine the efficacy of oral 882C87 compared with oral acyclovir in the treatment of localized herpes zoster in immunocompromised patients. To assess the safety and tolerance of oral 882C87 in immunocompromised patients.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Acyclovir Small molecule Oral
Subject Netivudine Small molecule Oral